Sunpointe LLC Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Sunpointe LLC acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,000 shares of the company’s stock, valued at approximately $71,000.

Other large investors also recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at about $42,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Xeris Biopharma in the third quarter valued at about $35,000. Quantbot Technologies LP acquired a new position in shares of Xeris Biopharma in the third quarter valued at about $44,000. Janney Montgomery Scott LLC grew its stake in shares of Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after acquiring an additional 5,500 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Xeris Biopharma by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock valued at $82,000 after acquiring an additional 11,239 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $3.97 on Friday. The firm’s 50-day moving average price is $3.48 and its two-hundred day moving average price is $3.14. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $4.10. The company has a market capitalization of $591.85 million, a price-to-earnings ratio of -8.82 and a beta of 2.61.

Analysts Set New Price Targets

Several equities analysts recently commented on XERS shares. HC Wainwright upped their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research note on Monday, November 11th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.